TriVascular, Inc

Founded in January 1998 by Michael V. Chobotov, Ph.D., and Joseph Humphrey, TriVascular has a history marked by significant corporate and product milestones. The company was acquired by Boston Scientific in April 2005, which had secured an option for the acquisition in 2002. However, Boston Scientific discontinued the EVAR program in 2006 and subsequently sold the business, then known as Boston Scientific Santa Rosa Corp., back to a private holding company, TV2 Holding Company, in March 2008 for $30 million. Following this, TriVascular continued its development and eventually filed for a $100 million IPO in March 2014, with sales of $20 million in the previous year. The company was ultimately acquired by Endologix, Inc. in a merger completed in February 2016.

TriVascular's flagship product is the Ovation Abdominal Stent Graft System, designed for EVAR procedures. This system features a stent graft—a fabric tube supported by a metal frame—delivered via a catheter to the site of the aneurysm. The graft creates a new path for blood flow, relieving pressure on the weakened aortic wall to prevent rupture. A key feature of the Ovation system is its low-profile delivery catheter, which at 14 French (4.7mm) in diameter, was the smallest available at the time of its approval, allowing for treatment in patients with smaller or diseased access vessels. The system also utilizes a unique polymer-filled sealing ring technology to secure the graft in place. The Ovation platform received its first FDA approval in November 2012 and subsequent approvals for enhanced versions like the Ovation Prime and Ovation iX systems, which offered improved ease of use and expanded patient applicability.